TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 41,955 shares of the biopharmaceutical company's stock after acquiring an additional 12,951 shares during the period. ProShare Advisors LLC's holdings in TG Therapeutics were worth $1,263,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its position in TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 975 shares during the period. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares during the period. Smartleaf Asset Management LLC grew its position in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp grew its position in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC purchased a new position in TG Therapeutics in the fourth quarter worth approximately $75,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Trading Up 1.0%

NASDAQ:TGTX traded up $0.35 during trading hours on Tuesday, reaching $34.92. 667,475 shares of the stock were exchanged, compared to its average volume of 2,980,721. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business has a 50-day moving average of $37.98 and a two-hundred day moving average of $34.36. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The company has a market capitalization of $5.54 billion, a price-to-earnings ratio of -349.37 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's revenue was up 90.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.07) earnings per share. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.